Biotechnology has been the stock market’s best performing sector over the last 4-5 years, according to Brad Loncer, a private investor with a biotech focus.
Cancer immunotherapy caught his attention. It is a treatment that uses your body’s own immune system to help fight cancer. A handful of drugs are already on the market and are revolutionizing treatment of melanoma.
Brad sees biotech as being a profitable part of any investor’s portfolio. Admittedly, it is volatile so he highly recommends we be diversified. That is why he created the Loncar Cancer Immunotherapy Index (LCINDX) – an equally weighted ETF.
Find out more at Loncarindex.com
- Miranda Marquit | Planting Money Seeds
- Joe Saul-Sehy | Stacking Benjamins
- Linda P. Jones | Be Wealthy and Smart
- Doug Goldstein | Rich as a King
For a quick bio of each of our show participants, head on over to our panelists page.